MedTrace Logo

A Survey of Lanadelumab in Participants With Hereditary Angioedema

NCT05397431 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

Lanadelumab

Lanadelumab 300 mg, subcutaneous injection every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2026-06-25
Completion
2026-06-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05397431 on ClinicalTrials.gov